Pharmaceuticals
By working for 18 of the 20 largest global pharmaceutical companies, our experienced team offers unrivalled understanding of this specialist market.
Significant challenges face the sector, including falling R&D productivity coupled with increasing generic competition and parallel imports, a reduction in government healthcare budgets, closer regulatory and investor scrutiny, and an increasing focus on drug safety. In addition, fewer drugs are reaching blockbuster status to support company growth, which places an even greater emphasis on patent protection. This means that drug pipelines are increasingly reliant on product / company acquisitions, licensing and collaborations to maintain earnings and reduce portfolio risks.
A major pharmaceutical company
Advised in relation to one of the world’s largest ever product liability cases.
GlaxoSmithKline
Acted in substantial litigation involving patents relating to two of GSK’s biggest selling products, Seroxat and Seretide. Also advised in connection with the alleged misuse of GSK’s confidential information in a component of GSK’s antibiotic Augmentin.
Successful representation of GSK before the French Supreme Court in cases involving the Hepatitis B vaccine.
Sinclair Pharma
Advised on its Italian and French acquisitions and its US licensing deal.
Takeda Europe
Advised in connection with various commercial agreements relating to the conduct of clinical trials, the marketing, promotion, supply and sale of pharmaceutical products and consultancy services.